样式: 排序: IF: - GO 导出 标记为已读
-
Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-04-22 Ghulam Rehman Mohyuddin, Aaron M. Goodman
Certain subsets of patients with multiple myeloma or its precursor conditions are overtreated with current approaches to therapy. Herein, we highlight several key areas where we believe de-escalation of treatment is needed. Dedicated trials to assess these de-escalation approaches and urgent changes to current clinical practices are needed.
-
Multiparametric MRI for characterization of the tumour microenvironment Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-04-19 Emily Hoffmann, Max Masthoff, Wolfgang G. Kunz, Max Seidensticker, Stefanie Bobe, Mirjam Gerwing, Wolfgang E. Berdel, Christoph Schliemann, Cornelius Faber, Moritz Wildgruber
-
ALND can be safely omitted for patients with sentinel-node macrometastases Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-04-18 David Killock
Omission of completion axillary lymph-node dissection (ALND) has been shown to mitigate lymphoedema without compromising survival outcomes in patients with clinically node-negative (cN0) breast cancer who have nodal metastasis detected upon sentinel lymph-node biopsy (SLNB), albeit in trials with limited statistical power and clinical representativeness. Now, data from the phase III SENOMAC trial in
-
Afami-cel provides a novel treatment option for rare sarcoma subtypes Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-04-18 Peter Sidaway
Patients with metastatic or unresectable synovial sarcoma or myxoid round cell liposarcoma (comprising 5–10% of all soft-tissue sarcomas) typically have limited long-term survival, especially after disease recurrence on first-line therapy. Now, data from the phase II SPEARHEAD-1 trial testing afamitresgene autoleucel (afami-cel), a CD4+ and CD8+ T cell product transduced with an affinity-enhanced MAGE-A4-specific
-
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-04-15 David H. Aggen, Jonathan E. Rosenberg
-
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-04-10 Hung-Yang Kuo, Kabir A. Khan, Robert S. Kerbel
-
Nucleic acid-based drugs for patients with solid tumours Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-04-08 Sebastian G. Huayamares, David Loughrey, Hyejin Kim, James E. Dahlman, Eric J. Sorscher
-
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-04-02 Peter Sidaway
Patients with locally advanced cervical cancer usually receive chemoradiotherapy (CRT) as first-line therapy, although this approach is generally not curative. Now, data from the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial demonstrate that adding the anti-PD-1 antibody pembrolizumab to CRT reduces the risk of disease progression in this setting. A total of 1,060 women with node-positive FIGO stage
-
Global epidemiology of epithelial ovarian cancer Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-03-28 Penelope M. Webb, Susan J. Jordan
-
Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-03-25 Diana Romero
Patients with recurrent, platinum-sensitive epithelial ovarian cancer (defined as disease relapse ≥6 months after first-line platinum-based chemotherapy) typically receive additional platinum-based regimens with or without bevacizumab, although most patients will have further relapse events. Now, data from one of the arms of the phase Ib FORWARD II trial show that the addition of the antibody–drug
-
Enhancing diagnostic precision in liver lesion analysis using a deep learning-based system: opportunities and challenges Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-03-22 Jeong Min Lee, Jae Seok Bae
A recent study reported the development and validation of the Liver Artificial Intelligence Diagnosis System (LiAIDS), a fully automated system that integrates deep learning for the diagnosis of liver lesions on the basis of contrast-enhanced CT scans and clinical information. This tool improved diagnostic precision, surpassed the accuracy of junior radiologists (and equalled that of senior radiologists)
-
IL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-03-21 David Killock
The efficacy of chimeric antigen receptor (CAR) T cell therapy for solid tumours has been disappointing to date. However, new data from a phase I trial in patients with recurrent high-grade gliomas (rHGGs) demonstrate the therapeutic potential of post-surgical intracranial delivery of CAR T cells targeting IL-13 receptor α2 (IL-13Rα2), a cancer-testis antigen that is often ectopically expressed in
-
A new standard of care for advanced-stage urothelial carcinoma Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-03-20 Peter Sidaway
Eligible patients with advanced-stage urothelial carcinoma (UC) typically receive platinum-based chemotherapy as first-line therapy, with median overall survival (OS) durations of ~15 months. Now, data from the phase III EV-302 trial demonstrate the superior efficacy of the antibody–drug conjugate enfortumab vedotin (EV) plus the anti-PD-1 antibody pembrolizumab in this setting. A total of 886 patients
-
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-03-20 Saman Maleki Vareki, Diwakar Davar
The composition of the gut microbiota has emerged as a tumour-extrinsic factor that modulates response to immune-checkpoint inhibitors (ICIs), although the lack of consistency in microbiota signatures across studies has limited their value as reliable biomarkers. Herein, we discuss a recent study in which longitudinal microbiome profiling identified several taxa that are persistently enriched in patients
-
Claudin 18.2 as a novel therapeutic target Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-03-19 Izuma Nakayama, Changsong Qi, Yang Chen, Yoshiaki Nakamura, Lin Shen, Kohei Shitara
-
Targeting cuproplasia and cuproptosis in cancer Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-03-14 Daolin Tang, Guido Kroemer, Rui Kang
-
The promise of AI in personalized breast cancer screening: are we there yet? Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-03-12 Despina Kontos
The benefits and potential harms of mammography-based screening for breast cancer are often a matter of debate. Here, I discuss the promises and limitations of a recent study that tested an artificial intelligence-based tool for the detection of breast cancer in digital mammograms in a large, prospective screening setting.
-
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-03-08 David Killock
Metastatic phaeochromocytomas and paragangliomas are very rare neuroendocrine cancers that occur in <1 per million individuals. A variety of treatment modalities have been used to manage these cancers, but with limited success and based on weak evidence. Now, the results of FIRSTMAPPP — probably the first randomized trial in this setting — demonstrate the efficacy of sunitinib. Owing to the potentially
-
Non-inferiority of simple versus radical hysterectomy in low-risk cervical cancer Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-03-06 Diana Romero
Radical hysterectomy is recommended for women with early stage cervical cancer, although the need for extensive surgery in those with FIGO stage IA2–IB1 disease that meets criteria for low risk (limited stromal invasion and no pelvic node involvement) is questionable based on retrospective evidence indicating that parametrial invasion is very rare in these patients. Now, the results of the phase III
-
Pegargiminaseimproves outcomes in nonepithelioid MPM Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-03-04 Peter Sidaway
Nonepithelioid malignant pleural mesotheliomas (MPMs), which comprise approximately a third of all mesotheliomas, often lack argininosuccinate synthetase 1 (ASS1) function (thus creating a metabolic dependence on exogenous arginine) and are therefore vulnerable to interventions that reduce arginine availability. Now, data from the phase II/III ATOMIC-Meso trial demonstrate the efficacy of pegargiminase
-
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-02-29 Masuko Katoh, Yohann Loriot, Giovanni Brandi, Simona Tavolari, Zev A. Wainberg, Masaru Katoh
-
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-02-29 Josep M. Llovet, Roser Pinyol, Mark Yarchoan, Amit G. Singal, Thomas U. Marron, Myron Schwartz, Eli Pikarsky, Masatoshi Kudo, Richard S. Finn
-
Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-02-29 Shogo Kumagai, Kota Itahashi, Hiroyoshi Nishikawa
-
Adjuvant chemotherapy improves OS in UTUC Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-02-22 David Killock
In 2020, adjuvant platinum-based chemotherapy became the standard of care for patients with muscle-invasive or locally advanced upper tract urothelial carcinoma of the ureter or renal pelvis (UTUC) based on disease-free survival (DFS) data from the POUT trial. Now, an update from POUT confirms that adjuvant treatment improves overall survival (OS) in this rare disease. In this phase III trial, 261
-
FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefit Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-02-21 Kelly J. Norsworthy, Rosa J. Lee-Alonzo, Richard Pazdur
In 2023, the US FDA approved several new cancer drugs and biologic agents, including seven small-molecule inhibitors, four bispecific T cell engagers, two anti-PD-1 antibodies and one cell therapy product. Regulatory focus areas included analyses of biomarker-positive subgroups that drive efficacy, equipoise in randomized controlled trials and a new authority to require confirmatory trials be underway
-
Targeting ATR in patients with cancer Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-02-20 Natalie Y. L. Ngoi, Patrick G. Pilié, Daniel J. McGrail, Michal Zimmermann, Katharina Schlacher, Timothy A. Yap
-
Tabelecleucel is effective in EBV-positive lymphoproliferative disease Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-02-19 Diana Romero
Epstein–Barr virus (EBV)-positive lymphoproliferative disease can occur following allogeneic haematopoietic stem-cell transplantation (HSCT) or solid organ transplantation (SOT). Several treatment options, including rituximab, are available for patients with this disease, although relapse occurs in ~50% and is associated with a poor prognosis. Now, the results of the phase III ALLELE trial demonstrate
-
KN046 shows tolerability and activity in TNBC Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-02-16 Peter Sidaway
Despite considerable research efforts, patients with advanced-stage triple-negative breast cancer (TNBC) generally receive chemotherapy and have a poor prognosis, with few effective targeted therapy or immunotherapy options available. Now, data from a phase II study demonstrate promising activity of the PD-L1 × CTLA4 bispecific antibody KN046 (a single-domain antibody Fc-fusion protein designed to
-
Dendritic cells as orchestrators of anticancer immunity and immunotherapy Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-02-07 Ignacio Heras-Murillo, Irene Adán-Barrientos, Miguel Galán, Stefanie K. Wculek, David Sancho
-
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-02-01 David Killock
Various immune-checkpoint inhibitors are approved as adjuvant therapies for high-risk melanoma (stage IIB–IV), but disease recurrence remains common. Now, new data indicate that the personalized therapeutic vaccine mRNA-4157 (V940) improves disease control when added to adjuvant pembrolizumab.
-
Promising early results with CAR NK cells Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-02-01 Diana Romero
Despite transforming the management of patients with haematological malignancies, autologous chimeric antigen receptor (CAR) T cell therapies have limitations. Now, the results of a phase I/II trial provide evidence of the feasibility, safety and efficacy of allogeneic CD19-directed CAR natural killer (NK) cells in patients with B cell malignancies.
-
Sotorasib dosing and incremental cost ineffectiveness — implications and lessons for stakeholders Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-01-30 Garth W. Strohbehn, Mark J. Ratain
The US FDA Accelerated Approval of sotorasib required the sponsor to conduct a randomized trial that compared the safety and efficacy of the approved dose with a lower dose. These results, recently disclosed, have important implications for patients, payers, oncologists and the pharmaceutical industry.
-
Combination strategies for advanced-stage urothelial carcinoma: a paradigm shift Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-01-26 Nimira Alimohamed, Srikala S. Sridhar
Durable responses with first-line platinum-based chemotherapy for advanced-stage urothelial carcinoma are rare, and patient outcomes are poor. Recently, CheckMate 901 became the first phase III trial to establish a significant overall survival benefit from a combined chemoimmunotherapy approach in this disease setting. Herein, we discuss key findings from CheckMate 901 and their implications in the
-
Repotrectinib effective in ROS1-fusion-positive NSCLC Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-01-26 Peter Sidaway
Patients with advanced-stage non-small-cell lung cancer (NSCLC) harbouring ROS1 fusions (~1–2% of all patients) can derive benefit from ROS1 tyrosine-kinase inhibitors (TKIs), such as entrectinib or crizotinib. Nonetheless, acquired resistance to these agents is common, and CNS activity is often limited. Now, data from TRIDENT-1, a large-cohort phase I/II trial, demonstrate the safety and efficacy
-
BRAF — a tumour-agnostic drug target with lineage-specific dependencies Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-01-26 Aphrothiti J. Hanrahan, Ziyu Chen, Neal Rosen, David B. Solit
-
Harnessing neoantigen-specific T cells for precision cancer immunotherapy Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-01-19 Marco Donia, Inge Marie Svane
Several novel personalized therapies focus on targeting neoantigens. Such strategies require the identification of suitable vaccine neoepitopes or neoantigen-specific T cell receptor (TCR) clonotypes. Herein, we discuss a recently published report that describes a combined transcriptional and phenotype signature, NeoTCRPBL, that enables the minimally invasive identification of rare neoantigen-specific
-
Lung cancer in patients who have never smoked — an emerging disease Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-01-09 Jaclyn LoPiccolo, Alexander Gusev, David C. Christiani, Pasi A. Jänne
-
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-01-08 Sebastian Klobuch, Tom T. P. Seijkens, Ton N. Schumacher, John B. A. G. Haanen
-
Myeloid-derived suppressor cells in cancer and cancer therapy Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-01-08 Samantha A. Lasser, Feyza G. Ozbay Kurt, Ihor Arkhypov, Jochen Utikal, Viktor Umansky
-
Exploring the next generation of antibody–drug conjugates Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-01-08 Kyoji Tsuchikama, Yasuaki Anami, Summer Y. Y. Ha, Chisato M. Yamazaki
-
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-01-08 Antonio Marra, Sarat Chandarlapaty, Shanu Modi
-
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-01-05 Garth W. Strohbehn, Bishal Gyawali
The FDA approval of perioperative pembrolizumab, an approach that combines neoadjuvant and adjuvant therapy with this agent, for patients with early stage non-small-cell lung cancer (NSCLC) contradicts its own stated standard for combination therapies. Given the large population of patients with early stage NSCLC and the high costs of pembrolizumab, whether the adjuvant component provides incremental
-
Benefit with MRD-guided treatment in CLL Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2024-01-02 Diana Romero
Patients with chronic lymphocytic leukaemia (CLL) typically receive first-line treatment with fludarabine, cyclophosphamide and rituximab (FCR), although other agents have shown promising efficacy over the past decade. These treatments include the combination of the BTK inhibitor ibrutinib and the BCL2 antagonist venetoclax. Now, results from the phase III FLAIR trial demonstrate the superiority of
-
Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option? Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-12-19 Pier Paolo M. Berton Giachetti, Giuseppe Curigliano
Recent results from the phase III PHILA trial demonstrate a benefit in terms of progression-free survival derived from the addition of pyrotinib to first-line chemotherapy plus trastuzumab in patients with metastatic HER2-positive breast cancer. Dual HER2 blockade with pyrotinib and trastuzumab is an effective therapeutic strategy but might increase the risk of gastrointestinal toxicity; therefore
-
Neoadjuvant chemoimmunotherapy is effective in locally advanced cervical cancer Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-12-18 Diana Romero
Chemoradiotherapy is the standard of care for women with locally advanced cervical cancer, although a substantial proportion will subsequently have disease recurrence. The addition of immune-checkpoint inhibitors (ICIs) to chemotherapy improves outcomes in the advanced-stage disease setting. Now, data from the single-arm phase II NACI trial demonstrate that neoadjuvant therapy with the ICI camrelizumab
-
Optimizing the FDA’s Project Optimus: opportunities and challenges Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-12-21 Simon Rodney, Udai Banerji
Through Project Optimus, the FDA calls for radical changes in the design of early phase trials to identify the optimal doses of oncology drugs to achieve maximal efficacy with better tolerability and patient acceptability. Herein, we discuss approaches that will enable the implementation of this initiative as well as some concerns that the draft guidance has raised in the oncology community.
-
PERSEUS triumphs — efficacy of daratumumab confirmed in transplant-eligible NDMM Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-12-20 David Killock
The standard-of-care treatment for patients with newly diagnosed multiple myeloma (NDMM) eligible for autologous stem cell transplantation includes four initial induction cycles and two further post-transplant consolidation cycles of bortezomib, lenalidomide and dexamethasone (VRd), followed by maintenance lenalidomide. Adding the anti-CD38 antibody daratumumab throughout such treatment improved disease
-
Mirvetuximab soravtansine superior to chemotherapy in platinum-resistant epithelial ovarian cancer Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-12-19 Peter Sidaway
Despite an initial response, most patients with epithelial ovarian cancer will develop acquired resistance to platinum-based chemotherapy. Later-line options typically involve non-platinum-based chemotherapy with or without bevacizumab, although these usually provide only limited benefit. Now, data from the phase III MIRASOL trial demonstrate the activity of the antibody–drug conjugate mirvetuximab
-
Pharmacological reactivation of p53 in the era of precision anticancer medicine Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-12-15 Amos Tuval, Charlotte Strandgren, Angelos Heldin, Mireia Palomar-Siles, Klas G. Wiman
-
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-12-11 Laura Morrison, Sibylle Loibl, Nicholas C. Turner
-
Tovorafenib effective against low-grade gliomas harbouring BRAF fusions Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-12-11 Peter Sidaway
The FDA approval of dabrafenib plus trametinib in March 2023 provided a much-needed targeted therapy option for patients with BRAFV600E-mutant low-grade glioma (LGG). Nonetheless, as a type I kinase inhibitor, dabrafenib is ineffective in patients with BRAF fusions, including KIAA1549–BRAF, which has been detected in ~35% of paediatric patients with LGG. Now, data from the phase II FIREFLY-1 trial
-
Patients with uncommon EGFR mutations also benefit from first-line osimertinib Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-12-06 Diana Romero
Around one-third of non-small-cell lung cancers (NSCLCs) are driven by mutations in EGFR. The most common of these alterations (in ~85% of patients) are exon 19 deletions and exon 21 L858R; the remaining alterations are referred to as uncommon. Osimertinib is the standard-of-care first-line therapy for patients with metastatic EGFR-mutated NSCLC, although limited evidence is available on efficacy in
-
Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-12-06 Rafael Rosell, María González-Cao
Recent results from the FLAURA2 and MARIPOSA-2 trials underline the continued role of chemotherapy in the treatment of patients with EGFR-mutated non-small-cell lung cancer in the era of targeted therapies. Herein, we argue that the most appropriate and rational sequence and/or combination of therapies remains a matter of discussion.
-
Personalizing adjuvant therapy for patients with colorectal cancer Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-11-24 Li Yang, Jinlin Yang, Andreas Kleppe, Håvard E. Danielsen, David J. Kerr
-
Combination neoadjuvant therapies are paving the way for bladder preservation to become the standard for selected patients Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-11-17 Jakob Klemm, Ekaterina Laukhtina, Shahrokh F. Shariat
Neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy with pelvic lymphadenectomy is the current standard therapy for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). A phase II trial testing treatment intensification by adding the immune-checkpoint inhibitor nivolumab to chemotherapy has yielded promising complete response rates, which suggests
-
Progress in systemic therapy for advanced-stage urothelial carcinoma Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-11-09 Rosa Nadal, Begoña P. Valderrama, Joaquim Bellmunt
-
From ESMO 2023: advances in lung cancer Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-11-03 Peter Sidaway
Among the many transformative developments reported at this year’s ESMO Congress, advances in the management of patients with lung cancer were particularly prominent and encompassed several different disease stages and settings.
-
From CHRYSALIS to PAPILLON: the metamorphosis of amivantamab into frontline therapy for NSCLC Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-11-03 David Killock
In 2021, data from the phase I CHRYSALIS trial supported the FDA Accelerated Approval of amivantamab, an EGFR–MET bispecific antibody, for the treatment of advanced-stage non-small-cell lung cancer (NSCLC) harbouring non-classical EGFR exon 20 insertion mutations after disease progression on platinum-based chemotherapy. Now, new data from the phase III PAPILLON trial demonstrate the efficacy of combining
-
THOR provides new data on the efficacy of erdafitinib Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-11-02 Diana Romero
The outcomes of patients with metastatic urothelial carcinoma (mUC) and non-muscle invasive urothelial carcinoma (NMIBC) following disease progression on standard-of-care therapy remain poor. Approximately 20% and 30% of such cancers, respectively, harbour FGFR alterations. Now, the results of three comparative trials in various disease settings provide insight into the role of the FGFR inhibitor erdafitinib
-
Activity of selpercatinib confirmed in phase III trials Nat. Rev. Clin. Oncol. (IF 78.8) Pub Date : 2023-11-02 Diana Romero
In May 2020, the FDA granted Accelerated Approval to the RET kinase inhibitor selpercatinib for patients with metastatic non-small-cell lung cancer (NSCLC) harbouring RET fusions and for those with metastatic medullary thyroid cancer (MTC) harbouring RET mutations. In September 2022, the approval of selpercatinib for NSCLC was converted into a regular approval. These regulatory decisions were all based